HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk
Clinical
Cardiology | Dermatology | Diabetes | Gastroenterology | Ophthalmology | Psychiatry | Pulmonology | Rheumatology
View All >>
Spotlight
COVID-19 | Sickle Cell Disease

Clinical News

View All >>

Proposed Aflibercept Biosimilar Provides Comparable Efficacy, Safety for DME

2 hours ago

By Kevin Kunzmann

Findings from the INSIGHT study suggest MYL-1701P may provide a new anti-VEGF biosimilar option to patients with the common form of vision loss.

Faricimab Exhibits Durable Efficacy in nAMD Treatment in TENAYA and LUCERNE

20 hours ago

By Connor Iapoce

The 48-week results suggest robust CST reduction and visual gains with faricimab up to every 16 week dosing, comparable with aflibercept ever 8-weeks.

Steven Yeh, MD: Artificial Intelligence Improves Diabetic Retinopathy Detection

21 hours ago

By Connor Iapoce

Dr. Yeh discusses how Innovations in AI may improve access for patients in resource limited setting and improve detection of vision-threatening diseases.

Dilsher Dhoot, MD: Analysis of OTX-TKI Implant Shows Promise for Wet AMD Treatment

23 hours ago

By Connor Iapoce

The data show 80% of patients were rescue-free up to 6 months with a single OTX-TKI implant injection.

Rishi Singh, MD: Efficacy of Pegcetacoplan for GA Based on 24-Month Data

October 02, 2022

By Connor Iapoce

A significant rate of reduction of geographic atrophy growth with pegcetacoplan was observed in both DERBY and OAKS over a 24-month period.

Conference Coverage
View All >>

Proposed Aflibercept Biosimilar Provides Comparable Efficacy, Safety for DME

2 hours ago

By Kevin Kunzmann

Findings from the INSIGHT study suggest MYL-1701P may provide a new anti-VEGF biosimilar option to patients with the common form of vision loss.

Faricimab Exhibits Durable Efficacy in nAMD Treatment in TENAYA and LUCERNE

20 hours ago

By Connor Iapoce

The 48-week results suggest robust CST reduction and visual gains with faricimab up to every 16 week dosing, comparable with aflibercept ever 8-weeks.

Dilsher Dhoot, MD: Analysis of OTX-TKI Implant Shows Promise for Wet AMD Treatment

23 hours ago

By Connor Iapoce

The data show 80% of patients were rescue-free up to 6 months with a single OTX-TKI implant injection.

Rishi Singh, MD: Efficacy of Pegcetacoplan for GA Based on 24-Month Data

October 02, 2022

By Connor Iapoce

A significant rate of reduction of geographic atrophy growth with pegcetacoplan was observed in both DERBY and OAKS over a 24-month period.

Video Series
View All >>
Expert Perspectives into the Utilization of JAK Inhibitors in Patients with Dermatologic Conditions
Safety and FDA Warnings for JAK Inhibitors in Dermatological Care
Characteristics of an Unhealthy RBC
Role of Unhealthy RBCs in Blood Disorders
Challenges with Current Treatments and Emerging Treatments for C. difficile Infection (CDI)
Foundational Trials for Fecal Microbiota Transplantation for C. difficile Infection
Impact of Treatment Response Time on Pediatric Atopic Dermatitis Burden
Real-World Experience With Dupilumab
Current FDA Approved JAK Inhibitors Use in Dermatological Care
Introduction to Janus Kinase (JAK) Inhibitors in Dermatology Care
The Importance of Patient Education in Atopic Dermatitis Management
Emerging Therapies and Future Directions for Pediatric Atopic Dermatitis
Patient Conversations Regarding RBC Health
Clinician Awareness of RBC Health and Related Laboratory Measurements
Monitoring Patients with C. difficile Infection (CDI) and rCDI
Video Interviews
View All >>
Steven Yeh, MD: Artificial Intelligence Improves Diabetic Retinopathy Detection
Dilsher Dhoot, MD: Analysis of OTX-TKI Implant Shows Promise for Wet AMD Treatment
Rishi Singh, MD: Efficacy of Pegcetacoplan for GA Based on 24-Month Data
Charles Wykoff, MD: Shifting the Treatment Paradigm with Pegcetacoplan for GA
Peter J Kertes, MD: Insights into the TALON Trial on Brolucizumab Versus Aflibercept
Efanesoctocog Alfa: The Breakthrough Hemophilia Therapy Candidate
Steven Pipe, MD: Novel Hemophilia A Therapy Offers Unprecedented Bleed Protection
Amit Thosani, MD: The Modern Field of Cardiac Arrhythmia Treatment
James Palmer, MD, FARS: Chronic Rhinosinusitis And Phase 3 Trials For Treatment Device
Sara Mednick, PhD: Why is Sleep so Beneficial?
Sara Mednick, PhD: Sleep is the Best Way to Get Smart
Dr. Reid Robison, MD: Treatment-Resistant Depression and Psychedelic Medicine Acceptance
Discussion On Older Homeless Mortality Rates, Future Research
Heart Team: The Evolving Role of Kidney Disease in CVD
Addressing Older Homeless Adult Health Concerns
Podcasts
View All >>
How AI, Machine Learning Are Providing an Edge on Interstitial Lung Disease
Cardiology & Nephrology Collaborations with Dr. Matthew Weir
John J. Miller, MD: A New Era For Psychiatric Medications
Nonprofit Research on Gene Therapy for Rare Ocular Diseases
Deconstructing Obstructive Sleep Apnea with Reena Mehra, MD, MS
Bindu Anand Balani, MD: Eradicating Hepatitis C Virus by 2030
FDA Approves Ruxolitinib: New Horizons in Vitiligo Care
The Biggest Discussions in Retina from the 2022 ASRS Annual Meeting
How Pegloticase Plus Methotrexate is Breaking Ground in Gout Care
What Ustekinumab Provides in Long-Term IBD Care
hcplive podcasts